PD44-11 EVALUATING THE QUALITY OF OVERACTIVE BLADDER PATIENT EDUCATION MATERIAL ON YOUTUBE USING THE PATIENT EDUCATION MATERIALS ASSESSMENT TOOL

1.14) for women and 1.06 (95% CI: 0.98, 1.14) for men. Results were similar in persons 65 years. IRs for bladder and prostate cancers were higher in both mirabegron and AM cohorts in the first 6 months after treatment initiation, suggesting protopathic bias. CONCLUSIONS: This large multi-country real-world study, with up to 6 years of follow up, found no evidence of an association between mirabegron use and risk of the studied cancers, compared to AMs, in either men or women.